CG Oncology Inc (CGON) Noticias

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec

IRVINE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical...

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

– Final positive CORE-001 safety and efficacy findings were published simultaneously online by Nature Medicine...

Form 8-K - Current report

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

IRVINE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical...

Form 8-K - Current report

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response (CR) Rate at Any Time in Bacillus Calmette...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel...

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

IRVINE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical...

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

IRVINE, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical...

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical...

CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer

- PIVOT-006 Phase 3 open-label trial of adjuvant cretostimogene is CG Oncology’s earliest disease stage clinical trial for patients with...

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone...